All Disease That May Require Acute Hospitalization Except for Phsychiatric DiseaseGASPNCT03049865

Gait Speed at Discharge as a Marker for Readmission

An observational study of All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease, run by Karolinska University Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record

Search all trials

Trial summary

The principal aim is to assess if a simple test, the time it takes to walk 10 meters for a patient about to be discharged after a hospital stay for an acute illness, is related to the risk of readmission. Read more about this study

Who is it for?: Ages 51 years and older
Conditions the study is for: All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease
How many people: 1,000 participants
Where: No sites listed yet
Study dates: 9 Feb 2017to 31 Dec 2027
Phase: Observational
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 51 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: All patients who are admitted to hospital from the emergency department are eligible for inclusion.

Who may be able to join

>50 years of age Patient discharged to home, or temporary short stay nursing home Expected survival >90 days The ability to read or understand the instructions and to give informed consent.

Who cannot join

Planned hospital stay, i.e. the patient was admitted electively The including investigator is directly involved in the care of the patient

About this study

Official title: Gait Speed at Discharge as a Marker for Readmission - The GASP Study

Conditions: All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

Readmission
Measured: 30 days

Secondary outcomes (2)

Readmissions
Measured: 90,180, 365 days
All-cause mortality
Measured: 6, 12, 24, 36, 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

9 Feb 201731 Dec 2027

First posted10 Feb 2017
Study start9 Feb 2017 (estimated)
Primary completion31 Dec 2017 (estimated)
Study completion31 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for All Disease That May Require Acute Hospitalization Except for Phsychiatric DiseaseStudies of the same condition, open and under way.
More trials run by Karolinska University HospitalThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 1,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT03049865
Sponsor's protocol ID: Dnr 2016/2174-31
Acronym: GASP
Status last verified: Feb 2017
First submitted: 8 Feb 2017
Last updated: 10 Feb 2017
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Study at a glance

From the registry record, last updated by the sponsor on 10 Feb 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Gait Speed at Discharge as a Marker for Readmission - The GASP Study
ClinicalTrials.gov ID: NCT03049865
Acronym / sponsor ID: GASP / Dnr 2016/2174-31
Conditions: All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease
Study type: Observational
Recruitment status: Not yet recruiting
Enrolment: 1,000 participants (estimated)
Lead sponsor: Karolinska University HospitalUniversity, hospital or other
Study start: 9 Feb 2017 (estimated)
Primary completion: 31 Dec 2017 (estimated)
Study completion: 31 Dec 2027 (estimated)
First posted: 10 Feb 2017 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Cohort
Time perspective: Prospective

Who may qualify

Ages: 51 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: All patients who are admitted to hospital from the emergency department are eligible for inclusion.

Key inclusion criteria (1 listed)

>50 years of age Patient discharged to home, or temporary short stay nursing home Expected survival >90 days The ability to read or understand the instructions and to give informed consent.

Key exclusion criteria (1 listed)

Planned hospital stay, i.e. the patient was admitted electively The including investigator is directly involved in the care of the patient

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

Readmission
Time frame: 30 days

2 secondary outcomes

Readmissions
Time frame: 90,180, 365 days
All-cause mortality
Time frame: 6, 12, 24, 36, 60 months

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2017.
Individual participant dataSharing planned: Undecided

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

The record lists no contact. Use the official record to reach the sponsor.

Questions about this trial

What is this clinical trial studying?

An observational study of All Disease That May Require Acute Hospitalization Except for Phsychiatric Disease, run by Karolinska University Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Readmission (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03049865.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2017.